<DOC>
	<DOC>NCT01001481</DOC>
	<brief_summary>The primary objective of this treatment review and feedback program is to quantify the risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia.</brief_summary>
	<brief_title>Schizophrenia Treatment Adherence Investigation (STAI)</brief_title>
	<detailed_description>The primary objective of this treatment review and feedback program is to quantify the risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia. Observational study - no study drug administered</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>Clinical diagnosis of schizophrenia or schizoaffective disorder according to DSMIV Currently treated in an outpatient clinic Able to provide informed consent Concurrent enrolment in clinical trials is acceptable Have completed all questions on the Drug Attitude Inventory (DAI10) and Medication Adherence Rating Scale (MARS) survey</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Treatment review</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Observational</keyword>
	<keyword>Prospective studies</keyword>
	<keyword>Australia</keyword>
</DOC>